Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
07 Oct 2021 | Liquidity and counterparty agreements | Download | |
04 Oct 2021 | Liquidity and counterparty agreements | Download | |
01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
28 Jul 2016 | Información sobre resultados (2) | ROVI releases the press release related to the 2016 first half results | Download |
28 Jul 2016 | Información sobre resultados | ROVI releases the presentation related to the 2016 first half results | Download |
05 Jul 2016 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the second quarter of 2016 | Download |
24 Jun 2016 | Información sobre dividendos | The Company informs about the dividends payment | Download |
31 May 2016 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to the agreements adopted by the 2016 General Shareholders Meeting | Download |